EMA and FDA Accept Marketing Applications for Chugai's Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKYO--(BUSINESS WIRE)-- #NMOSD--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application for satralizumab (development code: SA237), an anti-interleukin-6 (IL-6) receptor humanized recycling antibody, for the treatment of adult and adolescent patients with neuromyelitis optica spectrum disorder (NMOSD). EMA has granted Accelerated Assessment status for satralizumab. The U.S. Food and Drug Administration (FDA) h